Prodrug Nanoparticle Delivery Systems for Cancer Therapy

Prodrug nanoparticle delivery systems combine the principles of prodrug chemistry and nanotechnology to improve the specificity, efficacy and safety of anticancer agents. By chemically linking a therapeutic compound to a promoiety, prodrugs can remain inert during circulation and be activated in response to tumour-specific stimuli such as reductive or oxidative conditions, acidic pH or enzymatic activity. Self-assembly of these amphiphilic prodrugs into nanoparticles enhances their solubility and stability, allows high drug-loading without additional carriers and exploits the enhanced permeability and retention effect for passive tumour targeting. Stimuli-responsive linkages, notably redox-sensitive bonds and chalcogen bridges, enable controlled release within heterogeneous tumour microenvironments. Advances in rational molecular design, including the incorporation of RNA scaffolds or hybrid chalcogen bonds, have yielded nanoparticle platforms that achieve superior pharmacokinetics, selective activation and potent antitumour activity, while minimising systemic toxicity. These systems hold promise for translational oncology by offering multifunctional, carrier-free solutions that integrate imaging and therapeutic modalities.

Research from Nature Portfolio

Recent studies have refined the chemical scaffolds underpinning redox-responsive prodrug nanoassemblies. Hybrid chalcogen bonds, incorporating sulphur, selenium or tellurium, have demonstrated dual responsiveness to oxidative and reductive stimuli, yielding homodimeric prodrug nanoparticles with enhanced stability and on-demand drug release in heterogenous tumour microenvironments. Earlier work characterised the impact of sulfur, selenium and carbon linkages on nanoassembly behaviour, revealing that bond geometry and redox sensitivity govern self-assembly, pharmacokinetics and cytotoxic response. Separately, ultra-thermodynamically stable RNA four-way junction nanoparticles have been engineered to covalently load multiple paclitaxel prodrug molecules, surmounting issues of hydrophobic drug solubility, nanoparticle dissociation and immunogenicity. These innovations underscore the importance of precise molecular architecture in achieving targeted delivery and maximising therapeutic index.

Prodrug Nanoparticle Delivery Systems for Cancer Therapy publication trend

The graph below shows the total number of articles in prodrug nanoparticle delivery systems for cancer therapy across all publications each year (not limited to Nature Index journals).

Technical terms

Prodrug: An inactive precursor that is converted into an active therapeutic agent in response to specific biological conditions.

Nanoparticle: A particulate system in the 1–100 nm size range engineered for drug delivery with improved pharmacokinetics and targeting.

Self-assembly: The spontaneous organisation of molecules into ordered structures driven by non-covalent interactions.

Redox-responsivity: The ability of a material to undergo structural change or release cargo in oxidative or reductive environments.

Chalcogen bond: A non-covalent interaction involving group 16 elements (sulfur, selenium, tellurium) that stabilises nanoassemblies.

Enhanced permeability and retention effect: The preferential accumulation of nanoparticles in tumour tissue due to leaky vasculature and poor lymphatic drainage.

References

1. Probing the impact of sulfur/selenium/carbon linkages on prodrug nanoassemblies for cancer therapy. Nature Communications (2019).
2. Ultra-thermostable RNA nanoparticles for solubilizing and high-yield loading of paclitaxel for breast cancer therapy. Nature Communications (2020).
3. Nanoparticulation of Prodrug into Medicines for Cancer Therapy. Advanced Science (2021).
4. Hybrid chalcogen bonds in prodrug nanoassemblies provides dual redox-responsivity in the tumor microenvironment. Nature Communications (2022).
5. Indocyanine green potentiated paclitaxel nanoprodrugs for imaging and chemotherapy. Exploration (2022).
6. Probing the fluorination effect on the self-assembly characteristics, in vivo fate and antitumor efficacy of paclitaxel prodrug nanoassemblies. Theranostics (2021).